

# Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/ND48DC73C0CCEN.html>

Date: October 2020

Pages: 60

Price: US\$ 3,500.00 (Single User License)

ID: ND48DC73C0CCEN

## Abstracts

Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2020

### SUMMARY

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNA2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Alcohol Addiction, Psychiatric Disorders, Major Depressive Disorder, Neurology and Nicotine Addiction.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries,

conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2)

The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Overview

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Companies Involved in Therapeutics Development

Assuage Pharmaceuticals Inc

H. Lundbeck AS

Jeil Pharmaceutical Co Ltd

Kyung Dong Co Ltd

Sobrero Pharma AB

Sopharma AD

Suven Life Sciences Ltd

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNA2) - Drug Profiles  
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisinicline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JLP-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-8001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CHRN2 and CHRNA4 for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA4 and CHRN2 for Neurological and Psychiatric disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRN2 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRN2) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRN2) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRN2) - Product Development

## Milestones

### Featured News & Press Releases

Sep 10, 2020: Achieve Life Sciences announces presentation of Cytisinicline data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) virtual conference

Jul 31, 2020: Achieve announces Patent granted in the U.S. for novel analogs of Cytisinicline for use in CNS and Addiction Indications

Jun 29, 2020: Achieve announces successful results from the investigator-initiated RAUORA head-to-head non-inferiority clinical trial comparing Cytisinicline and Chantix (varenicline) as a treatment to quit smoking

Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program

Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference

Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study

Sep 13, 2019: Achieve Life Sciences announces final phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and final data from the phase 2b ORCA-1 trial

Jul 23, 2019: Achieve Life Sciences extends collaboration with the National Institutes of Health to advance the development of Cytisinicline for Smoking Cessation

Jun 21, 2019: Achieve Life Sciences announces Phase 2b ORCA-1 trial data accepted for oral presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

Jun 11, 2019: Achieve Life Sciences announces statistically significant improvement in quit rates for simplified cytisinicline dosing schedule in phase 2b ORCA-1 dose-selection trial

May 30, 2019: Achieve announces patent granted in the U.S. for novel formulation of Cytisinicline

Apr 24, 2019: Achieve Life Sciences announces last subject, last visit completed in phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation

Apr 02, 2019: Achieve Life Sciences announces successful completion of the second and final DSMC review of phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation

Feb 22, 2019: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger

Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indication, H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by Assuage Pharmaceuticals Inc, H2 2020  
Pipeline by H. Lundbeck AS, H2 2020  
Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020  
Pipeline by Kyung Dong Co Ltd, H2 2020  
Pipeline by Sobrera Pharma AB, H2 2020  
Pipeline by Sopharma AD, H2 2020  
Pipeline by Suven Life Sciences Ltd, H2 2020  
Dormant Products, H2 2020  
Dormant Products, H2 2020 (Contd..1), H2 2020  
Discontinued Products, H2 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

## I would like to order

Product name: Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/ND48DC73C0CCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND48DC73C0CCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970